Details
Stereochemistry | RACEMIC |
Molecular Formula | C14H22N4O2 |
Molecular Weight | 278.3501 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@](CCCCCC)([C@@H](C)O)N1C=NC2=C1N=CNC2=O
InChI
InChIKey=RSMDQPNZAPMDJC-MNOVXSKESA-N
InChI=1S/C14H22N4O2/c1-3-4-5-6-7-11(10(2)19)18-9-17-12-13(18)15-8-16-14(12)20/h8-11,19H,3-7H2,1-2H3,(H,15,16,20)/t10-,11+/m1/s1
Molecular Formula | C14H22N4O2 |
Molecular Weight | 278.3501 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Nosantine (NPT 15392) is a novel heterocyclic immunomodulatory compound related to inosine in structure and isoprinosine in action. Nosantine enhances a variety of lymphoid functional activities including proliferative responses to various antigenic and mitogenic stimuli. Such activities imply potential therapeutic use in immunodeficiency related to defects of the thymus and thymus-derived lymphocytes. In head and neck cancer patients the drug induced transitory, immune stimulation during or after treatment without any side effects. NPT 15392 seemed to selectively exert an action on T lymphocytes. Nosantine was found to be a potent and relatively selective inhibitor of mouse lymphocyte cyclic GMP phosphodiesterase, with IC50 values 15-180 times greater for cyclic AMP than cyclic GMP phosphodiesterases. Immunopharmacologic activities of NPT 15392 may include specific cyclic GMP phosphodiesterase inhibition as one of several possible mechanisms.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Effects of NPT 15392 in vitro on human leukocyte functions. | 1982 |
|
Selective inhibition by NPT 15392 of lymphocyte cyclic GMP phosphodiesterase. | 1984 Nov 1 |
|
Kinetic analysis of the immunopotentiating effect of the hypoxanthine analogue, NPT-15392, on the interleukin-2 production potential of human lymphocytes. | 1986 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6213574
Nosantine was administered in a single intraperitoneal injection to Balb/c mice at a dose of 0.1 mg/kg.
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6093811
Nosantine (NPT 15392) is a potent and relatively selective inhibitor of mouse lymphocyte cyclic GMP phosphodiesterase, with IC50 values 15-180 times greater for cyclic AMP than cyclic GMP phosphodiesterases. The greatest inhibition by NPT 15392 was found using 10 uM substrate, and inhibition was greater in membrane than soluble forms of phosphodiesterase. A major form of cyclic GMP phosphodiesterase was inhibited effectively by NPT 15392 in a competitive manner (Ki = 50 uM). Cyclic AMP phosphodiesterase activity in the same fraction, but representing only a fifth of the total activity, was also inhibited (Ki = 70 uM). Membrane bound enzymes were solubilized and separated into three peaks. One with high affinity for cyclic GMP was strongly inhibited (Ki = 10 uM) by NPT 15392.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:22:01 GMT 2023
by
admin
on
Fri Dec 15 16:22:01 GMT 2023
|
Record UNII |
NYM432G79C
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C308
Created by
admin on Fri Dec 15 16:22:01 GMT 2023 , Edited by admin on Fri Dec 15 16:22:01 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL2304038
Created by
admin on Fri Dec 15 16:22:01 GMT 2023 , Edited by admin on Fri Dec 15 16:22:01 GMT 2023
|
PRIMARY | |||
|
100000083623
Created by
admin on Fri Dec 15 16:22:01 GMT 2023 , Edited by admin on Fri Dec 15 16:22:01 GMT 2023
|
PRIMARY | |||
|
NYM432G79C
Created by
admin on Fri Dec 15 16:22:01 GMT 2023 , Edited by admin on Fri Dec 15 16:22:01 GMT 2023
|
PRIMARY | |||
|
DTXSID80997929
Created by
admin on Fri Dec 15 16:22:01 GMT 2023 , Edited by admin on Fri Dec 15 16:22:01 GMT 2023
|
PRIMARY | |||
|
135474265
Created by
admin on Fri Dec 15 16:22:01 GMT 2023 , Edited by admin on Fri Dec 15 16:22:01 GMT 2023
|
PRIMARY | |||
|
5663
Created by
admin on Fri Dec 15 16:22:01 GMT 2023 , Edited by admin on Fri Dec 15 16:22:01 GMT 2023
|
PRIMARY | |||
|
C66246
Created by
admin on Fri Dec 15 16:22:01 GMT 2023 , Edited by admin on Fri Dec 15 16:22:01 GMT 2023
|
PRIMARY | |||
|
SUB09382MIG
Created by
admin on Fri Dec 15 16:22:01 GMT 2023 , Edited by admin on Fri Dec 15 16:22:01 GMT 2023
|
PRIMARY | |||
|
76600-30-1
Created by
admin on Fri Dec 15 16:22:01 GMT 2023 , Edited by admin on Fri Dec 15 16:22:01 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |